Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opevesostat (MK-5684) Alone or in Combination for mCRPC
NCT06353386Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 2 trial of opevesostat in prostate cancer (PCa), sponsored by Merck & Co.. Started May 2024; status: active, not recruiting.
02
Drugs
opevesostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06353386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353386.